<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The epidemiology of Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in populations at different risk for EBV-associated diseases indicates significant differences between the populations </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> takes place much earlier in Uganda, where <z:hpo ids='HP_0000001'>all</z:hpo> children are infected before the age of 2 to 3 years, than in Southeast Asia, where nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> is prevalent </plain></SENT>
<SENT sid="2" pm="."><plain>It is proposed that such early <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in Equatorial Africa is related to the risk for Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Four possible interventions to control EBV-associated diseases are presented: (a) simple hygienic measures to delay natural <z:e sem="disease" ids="C0948192" disease_type="Disease or Syndrome" abbrv="">primary infection</z:e> by EBV; (b) EBV vaccine; (c) intervention against cofactors such as <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; and (d) characterization of high-risk groups to allow early detection and successful treatment </plain></SENT>
</text></document>